RelB-Dependent Stromal Cells Promote T-Cell Leukemogenesis

Nuno R. dos Santos1,2*, Maryvonne Williame1,2, Stéphanie Gachet1,2, Françoise Cormier1,2, Anne Janin3, Debra Weih4, Falk Weih4, Jacques Ghysdael1,2

1 Institut Curie, Centre de Recherche, Orsay, France, 2 CNRS UMR146, Orsay, France, 3 INSERM Unité 728, Université Paris VII, Hôpital Saint-Louis, Paris, France, 4 Leibniz-Institute for Age Research – Fritz-Lipmann-Institute (FLI), Jena, Germany

Abstract

Background: The Rel/NF-κB transcription factors are often activated in solid or hematological malignancies. In most cases, NF-κB activation is found in malignant cells and results from activation of the canonical NF-κB pathway, leading to RelA and/or c-Rel activation. Recently, NF-κB activity in inflammatory cells infiltrating solid tumors has been shown to contribute to solid tumor initiation and progression. Noncanonical NF-κB activation, which leads to RelB activation, has also been reported in breast carcinoma, prostate cancer, and lymphoid leukemia.

Methodology/Principal Findings: Here we report a novel role for RelB in stromal cells that promote T-cell leukemogenesis. RelB deficiency delayed leukemia onset in the TEL-JAK2 transgenic mouse model of human T acute lymphoblastic leukemia. Bone marrow chimeric mouse experiments showed that RelB is not required in the hematopoietic compartment. In contrast, RelB plays a role in radio-resistant stromal cells to accelerate leukemia onset and increase disease severity.

Conclusions/Significance: The present results are the first to uncover a role for RelB in the crosstalk between non-hematopoietic stromal cells and leukemic cells. Thus, besides its previously reported role intrinsic to specific cancer cells, the noncanonical NF-κB pathway may also play a pro-oncogenic role in cancer microenvironmental cells.

Introduction

The Rel/NF-κB transcription factors function in multiple biological processes, including development, immunity, inflammation, and response to cellular stress [1]. NF-κB subunits are often activated in solid or hematological malignancies as the result of rearrangements/mutations in their genes or in genes encoding components of the NF-κB signaling pathway, persistent autocrine or paracrine stimulation through specific cell surface receptors, or viral or cellular oncprotein activity [for review see [2,3]]. NF-κB activation in cancer cells has been shown to activate genes involved in cell survival, proliferation, angiogenesis, invasion, and chemoresistance being therefore an important target for cancer therapy. Recently, an important function for the canonical NF-κB pathway in inflammatory cells infiltrating several types of solid tumors has been brought to light. NF-κB activation in those cells leads to the production of cytokines, growth factors, and angiogenic factors that promote malignant conversion and progression [for review see [3]].

The NF-κB proteins are transcriptional regulators that bind cognate DNA elements as homo- or heterodimers. NF-κB activity is controlled by interaction with IκB (inhibitor of NF-κB) proteins and only when these are degraded by the proteasome, following serine phosphorylation by IκB kinases (IKK) and ubiquitination, are NF-κB dimers released. The NF-κB/Rel family comprises five members (RelA, RelB, c-Rel, p50/p105, and p52/p100) sharing the conserved Rel homology domain, which is responsible for DNA binding, nuclear localization, dimerization, and IκB binding. In contrast to RelA (p65), RelB, and c-Rel, the p50 and p52 proteins, which derive from proteolytic processing of the p105 and p100 precursor proteins, respectively, lack transactivation domains. The p50 and p52 proteins act thus as transcriptional repressors, except when forming heterodimers with other NF-κB members or when interacting with other transcriptional activators, such as the BcI3 protein [for review see [1]].

Two main NF-κB activation pathways have been identified [1]. The canonical NF-κB activation pathway, which is triggered by an array of stimuli such as proinflammatory cytokines, antigen receptors, Toll-like receptors, and cellular stress, relies on IKKβ (IKK2)/IKKγ (NEMO)-dependent IκB phosphorylation and degradation and results in RelA and/or c-Rel activation. Disruption of the canonical pathway in immune cells impairs innate and acquired immune responses in a cell-autonomous or
non-cell-autonomous manner (for review see [4]). The noncanonical NF-κB activation pathway, which can be activated by specific members of the TNF receptor family (e.g., lymphotoxin β receptor [LTBR] and BAFF receptor [BAFF-R]) depends on IKK2 (IKK1) and NIK kinase activity but not on IKKβ or IKKγ [1]. Upon stimulation, IKK2 phosphorlotes p100 on C-terminal serine residues and induces its ubiquitin-dependent processing to generate p52. When released from p100 sequestration, p52:RelB, and, as recently shown, p50:RelA dimers shuttle to the nucleus to activate transcription of specific target genes [5–9].

Disruption of the noncanonical pathway also affects immune cell function, impairing either lymphoid organogenesis due, at least in part, to defective LTβR signaling, or mature B cell function and maintenance due to defective BAFF-R signaling [9]. Furthermore, inactivation of the noncanonical pathway breaks down central tolerance as a result of impaired generation of medullary thymic epithelial cells (mTEC), which are essential for negative selection of autoreactive T cells [9–11].

Most studies in human lymphoid leukemia and lymphoma have identified canonical NF-κB activation in leukemic cells. For example, NF-κB activation is frequently observed in Hodgkin’s lymphomas due to activation of the CD30, CD40, and RANK receptors or due to inactivating mutations in the Isk2-encoded gene [12]. Activation of p50 homodimers and p50:RelA heterodimers was detected in all major subtypes of human acute lymphoblastic leukemia (ALL) [13]. The v-rel oncogene, the retroviral counterpart of c-rel, induces aggressive leukemia/lymphoma in chicken and transgenic mice [14].

Canonical NF-κB activity was also found in T-ALL induced in mice following expression of a Tal1 transgene or of intracellular Notch1 (Notch1-IC) oncogenic protein [15,16]. Finally, both the canonical and noncanonical NF-κB pathways were found to be activated by viral oncoproteins, in particular the HTLV1-encoded Tax protein in adult T-cell leukemia and the EBV-encoded LMP1 protein in B-cell lymphoma [12].

Several reports indicate that the noncanonical NF-κB pathway is also activated in specific subtypes of lymphoid leukemia and lymphoma (for review see [9,12,17]). Chromosomal translocations disrupting the Nkb2 gene that generate truncated p100 proteins and constitutive processing of p100 to p52 were identified in cutaneous T-cell lymphoma, and, more rarely, in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma [9,12,17]. Transgenic expression of a truncated p100 protein led to the development of B-cell lymphomas in mice, thus demonstrating the oncogenic potential of Nkb2 mutations [18].

Recently, genetic alterations in components of the noncanonical and canonical NF-κB pathways (e.g., NIK, TRAF3, C1LD, BIRC2/ BIRC3, CD40, NFκB1, or NFκB2) resulting in their activation have been identified in multiple myeloma [19,20].

In the present report we assessed the role of NF-κB proteins in a transgenic mouse model for human T-ALL induced by the TEL-JAK2 fusion protein [21,22] and uncovered a specific role for RelB in T-cell leukemia development. Using RelB knockout mice we found that RelB assisted TEL-JAK2-induced T-cell leukemogenesis. Interestingly, bone marrow chimeric mouse experiments showed that RelB is not required in the hematopoietic compartment but plays a role in radio-resistant stromal cells to favor leukemia onset and increase disease severity.

Results

TEL-JAK2 leukemic cells display RelA and RelB activation

To assess the NF-κB activation status in leukemic T cells from EpiSRα2-TEL-JAK2 transgenic mice, we performed electrophoretic mobility shift assays (EMSA) on nuclear extracts using an NF-κB-specific oligonucleotide probe. Nuclear extracts from TEL-JAK2 tumor cells showed significantly higher levels of NF-κB-DNA-binding activity, visible as two bands with different mobility, as compared to control thymocyte nuclear extracts (Figure 1A). To determine which NF-κB members were activated in TEL-JAK2 leukemic cells, we pre-incubated nuclear extracts with specific NF-κB antibodies that either supershift or inhibit protein/DNA complexes. A p50/NF-κB1 antibody quantitatively supershifted band I and most of band II in TEL-JAK2 leukemic cells (Figure 1B, compare lanes 1 and 2). The remaining NF-κB activity in band II was inhibited by a p52/NF-κB2 antibody (Figure 1B, lane 3), indicating the presence of both proteins in different complexes. Band II complexes also included RelA and RelB since the RelA antibody inhibited a slowly migrating complex within band II (Figure 1C, lane 2 and Figure S1A, lane 3), leaving intact a faster migrating complex recognized by the RelB antibody (Figure 1C, lanes 3 and 4 and Figure S1A, lane 4).

To identify the NF-κB dimers activated in TEL-JAK2 leukemic cells, we performed supershift analyses combining different antibodies. Combination of RelA and p50 antibodies yielded the

Figure 1. Activation of NF-κB transcription factors in TEL-JAK2 leukemic cells. (A) Nuclear extracts obtained either from freshly isolated wild-type control thymocytes (WT thy) or from thymus (thy) or lymph node (LN) leukemic cells from two representative TEL-JAK2 (TJ2) diseased mice (n = 66 and n = 13) were analyzed by electrophoretic mobility shift assays (EMSA) using the NF-κB-binding Ig-κB oligonucleotide probe. Similar results were obtained with more than 20 primary leukemic samples. Bands labeled I and II (arrowheads) indicate specific NF-κB complexes as assessed by competitive EMSA (data not shown). An Ets-specific probe (E74) was used for nuclear extract normalization. (B–D) Antibody supershift analysis of Ig-κB-bound complexes using the indicated antibodies was performed on leukemic nuclear extracts from individual TEL-JAK2 tumors (tumor n = 1284 in panel B and D; tumor n = 38 in panel C). Open arrows indicate supershifted complexes, filled arrows identify the different NF-κB complexes, and the asterisk indicates a nonspecific band. p50, p52, RelA, and RelB DNA-binding activity in TEL-JAK2 leukemic cells was also detected using a palindromic NF-κB probe derived from the IL2Rα promoter, indicating that the previous results were not biased by differential DNA recognition by NF-κB proteins.

doi:10.1371/journal.pone.0002555.g001
same migration pattern as that observed with p50 antibody alone (Figure 1D, compare lanes 2 and 5), indicating that RelA heterodimerized with p50. Combination of the RelB antibody with p50 and RelA antibodies inhibited the remaining complex (Figure 1D, compare lanes 5 and 6), which, given that RelB is unable to form homodimers [23], corresponds to p52:RelB heterodimers. Likewise, combination of the RelB antibody with p52 and RelA antibodies inhibited a complex that corresponded to p50:RelB heterodimers (Figure 1D, compare lanes 7 and 8). In sum, supershift analyses discerned the presence of p50:p50 homodimers as well as p50:RelA, p50:RelB, and p52:RelB heterodimers in TEL-JAK2 leukemic cells.

**Nfkb1** deficiency does not affect TEL-JAK2-induced T-cell leukemia development

To assess the role of NF-κB proteins in TEL-JAK2-induced leukemogenesis, we bred EμSRα-TEL-JAK2 mice with mice deficient for specific NF-κB genes. To prevent p50-containing complex formation, we first bred EμSRα-TEL-JAK2 mice with Nfkb1−/− mice, which do not express the NF-κB proteins p50 and its precursor p105 and do not show any thymocyte maturation defects [24]. EμSRα-TEL-JAK2;Nfkb1−/− and EμSRα-TEL-JAK2;Nfkb1−/− littermate mice developed T-cell leukemia with full penetrance and similar latency (Figure 2A; median survival of 12 weeks). In addition, Nfkb1−/− deficient leukemic cells presented a cell surface marker phenotype (expression of variable levels of CD4, CD8, CD24, CD25, and TCRβ/CD3δ) similar to that of Nfkb1−/− proficient cells (data not shown) and characteristic of transgenic TEL-JAK2 leukemia [21,25].

EMSA analyses showed that the TEL-JAK2;Nfkb1−/− leukemic cells displayed severely reduced NF-κB activity and, as expected, did not display any p50 DNA-binding activity, as evidenced by the lack of p50 homodimers (band I) (Figure 2B). Interestingly, no RelA DNA-binding activity was detectable in nuclear extracts from TEL-JAK2;Nfkb1−/− leukemic cells (Figure 2C). This was not due to an intrinsic inability to activate RelA in these cells, since TEL-JAK2;Nfkb1−/− leukemic cells induced p52:RelA and RelA:RelA DNA-bound dimers upon in vitro treatment with PMA plus ionomycin (Figure S2). This result suggests that activation of p50 and/or RelA does not play a nonredundant role in TEL-JAK2 leukemogenesis. The only DNA/protein complexes identified in TEL-JAK2;Nfkb1−/− leukemic cells were p52:RelB heterodimers, since formation of this complex was inhibited by antibodies against either p52 or RelB, but not by p50-, c-Rel-, or RelA-specific antibodies (Figure 2C and data not shown).

**Generation of viable Relb-deficient mice**

Since TEL-JAK2;Nfkb1−/− leukemic cells only presented constitutive p52:RelB activity, we set out to evaluate the role of RelB in TEL-JAK2-induced leukemogenesis by generating Relb−/− TEL-JAK2 transgenic mice. Relb−/− deficient mice present fatal T-cell-dependent multiorgan inflammation, a phenotype resulting from the absence of mTECs, which are essential for negative selection of autoreactive T cells [26–28]. To generate viable Relb−/− deficient mice, these were bred with Tcrα−/− mice (Figure S3A and data not shown), demonstrating that Tcra deficiency rescued the inflammatory phenotype observed in Relb−/− deficient mice [26–28]. In line with previous findings [28], we observed that mature T-cell deficiency in Relb-null mice prevented splenomegaly and splenic myeloid hyperplasia (data not shown).

Relb−/− deficient mice present defective development of thymus and secondary lymphoid organs [26,27,29]. The defective lymph node development linked with Relb deficiency was not rescued by mature T-cell deficiency (Figure S3B), showing that it is a non-T-cell-dependent phenotype. In contrast, Tcrα−/−:Relb−/− mice presented thymi of size similar to that of Tcrα−/−:Relb+/− littermates (data not shown), confirming the notion that the severe thymic atrophy seen in Relb-null mice is mainly due to T-cell dependent multiorgan inflammation [30]. In contrast to wild-type thymi, Tcrα−/−:Relb−/− thymi presented reduced and disorganized medulla with few scattered *Ulex europaeus* agglutinin 1 (UEA-1)-positive mTECs (Figure 3A), a phenotype caused by the absence of mature T-cell crosstalk with the thymic stroma [11,31,32]. Tcrα−/−:Relb−/− thymi, like Relb−/− thymi [26,27,31], lacked distinctive medulla and did not present any UEA-1+ mTECs (Figure 3A). Despite a 1.4-fold reduction in thymocyte cellularity in Tcrα−/−:Relb−/− mice as compared to Tcrα−/−:Relb+/− mice (Figure 3B), early thymocyte development proceeded similarly in both Relb-deficient and Relb-proficient mice. Indeed, both groups of mice presented similar

**Figure 2. Nfkb1 deficiency did not impair TEL-JAK2-induced T-cell leukemogenesis.** (A) Kaplan-Meier leukemia-free survival curves for EμSRα-TEL-JAK2 transgenic mice deficient or not for the Nfkb1 gene. No statistically significant differences were observed. The number of mice in each group is given between parentheses. (B) Leukemic cell nuclear extracts from representative TEL-JAK2;Nfkb1−/− (mice n=110 and n=121) and TEL-JAK2;Nfkb1−/− (mice n=109 and n=140) mice were analyzed by EMSA using the Ig-k and Sp1 probes. L and II indicate specific DNA-bound NF-kB complexes. Note the absence of band I (p50 homodimers) in Nfkb1−/− samples. (C) Antibody supershift analysis using the indicated antibodies on Ig-k bound complexes derived from representative TEL-JAK2;Nfkb1−/− (mouse n=140) leukemic cells. Band II corresponds to p52/RelB DNA-bound heterodimers. The asterisk indicates a non NF-κB-specific band.

doi:10.1371/journal.pone.0002555.g002
proportions of CD4+CD8− double negative (DN), CD8 immature single positive, and CD4+CD8+ double positive (DP) thymocytes (Figure 3C and data not shown). As expected, due to the Tcrα mutation no CD4 and CD8 single-positive (SP) cells were observed in the two groups of mice. The proportion of DN subsets, as defined by CD25 and CD44 expression, and TCRγδ T-cell development was also unaffected by RelB deficiency in Tcrα−/−:Relb−/− mice (Figure 3C and Figure S4).

### Relb deficiency delays the onset of TEL-JAK2-induced T-cell leukemia

Our previous studies have shown that breeding of TEL-JAK2 transgenic mice on a Tcrα-deficient background does not delay leukemia onset and incidence [25], although TEL-JAK2;Tcrα−/− leukemic cells showed reduced RelA DNA-binding activity as compared to Tcrα-proficient leukemic cells while maintaining a similar level of RelB DNA binding activity (Figure S5). In contrast, when EpSRz-TEL-JAK2 mice were bred on a Tcrα−/−:Relb−/− background, we found that these mice developed T-cell leukemia with statistically significant delayed onset as compared to TEL-JAK2;Tcrα−/−:Relb−/− littermates (median survival of 18.5 and 13 weeks, respectively, P<0.01) (Figure 4A). Diseased mice from both groups presented leukemic cells in thymus, spleen, lymph nodes, bone marrow, liver, and lungs (Figure S6 and data not shown). However, TEL-JAK2;Tcrα−/−:Relb−/− mice presented significantly reduced tumor load in thymus and lymph nodes, as compared to Relb-proficient littermates (Figure 4B). Similar to Relb-proficient cells, Relb-deficient leukemic cells presented the variable levels of CD4, CD8, CD24, and CD25 cell surface markers that characterize TEL-JAK2 leukemic cells (Figure S7). TEL-JAK2;Tcrα−/−:Relb−/− leukemic cells showed similar p50:p50 and p50:RelA NF-kB DNA-binding activity as TEL-JAK2;Tcrα−/−:Relb−/− leukemic cells (data not shown), indicating that RelB inactivation did not lead to selection of leukemic cells displaying enhanced DNA-binding activity of other NF-kB family members. Together, these results reveal a non-redundant function for RelB in TEL-JAK2-induced leukemogenesis. However, because RelB deficiency affects all mouse tissues, these results do not distinguish whether RelB function is required intrinsically in the hematopoietic cells targeted by TEL-JAK2, and/or whether it is required in non-leukemic cells from the tumor microenvironment to support TEL-JAK2-induced leukemogenesis.

### Relb deficiency in the hematopoietic compartment does not affect TEL-JAK2-induced T-cell leukemogenesis

To analyze whether the function of RelB in TEL-JAK2-induced leukemogenesis reflected an intrinsic role in the hematopoietic compartment, we generated bone marrow injection chimeric mice. Bone marrow cells obtained from either TEL-JAK2;Tcrα−/−:Relb−/− or TEL-JAK2;Tcrα−/−:Relb−/− non-diseased mice were intravenously injected into wild-type (WT), lethally irradiated recipient mice (Figure 5A). Both groups of bone marrow chimeric mice developed T-cell leukemia with similar onset (median survival of 18 and 17 weeks for TEL-JAK2;Tcrα−/−:Relb−/− → WT and TEL-JAK2;Tcrα−/−:Relb−/− → WT mice, respectively) (Figure 5B). Diseased chimeric mice of both groups developed leukemia affecting the thymus, frequently in association with pleural effusion, lymph nodes, bone marrow, and occasionally spleen and liver (data not shown). No significant difference in lymphoid organ invasion and leukemic cell surface marker expression was observed between the two experimental groups (Figure S8 and data not shown). Of note, under these experimental conditions non-TEL-JAK2 transgenic Tcrα−/−:Relb−/− and Tcrα−/−:Relb−/− bone marrow donor cells

---

Figure 3. **Tcrα:Relb double deficient mice present defective thymic microarchitecture without impairment of double positive thymocyte development.** (A) Thymi from mice with the indicated genotypes were stained by H&E (panels a–c) or with UEA-1 lectin, a cell surface marker of medullary thymic epithelial cells (d–f). Note the clear distinction between medulla (M) and cortex (C) in the wild-type thymus. (B) Thymocyte total cell counts were plotted for Tcrα−/−:Relb+/+ (n = 7) and Tcrα−/−:Relb−/− (n = 8) mice aged from 12–16 weeks. (C) CD4, CD8 cell surface immunostaining of total thymocytes (top panels) and CD25, CD44 staining of Thy1.2+, CD4/CD8 double negative cells (bottom panels) of representative mice of the indicated genotypes.

doi:10.1371/journal.pone.0002555.g003
RelB deficiency in radiation-resistant non-hematopoietic cells delays the onset of TEL-JAK2-induced T-cell leukemia

Since RelB is expressed in thymic and lymph node non-hematopoietic cells and since genetic experiments have shown that RelB plays an important role in shaping thymus and lymph node architecture during mouse development [26,27,33], we analyzed whether RelB could play a role in leukemogenesis through a hematopoietic cell-extrinsic mechanism. First, we assessed the ability of Tcra−/−;Relb−/− mice to support normal development of Relb+/+ T cells. Therefore, Tcra−/−;Relb+/+ bone marrow cells were adaptively transferred into lethally irradiated Tcra−/−;Relb−/− (Tcra−/−→Tcra−/−;Relb−/−) or Tcra−/−;Relb+/+ (Tcra−/−→Tcra−/−;Relb+/−) recipient mice. Expression of CD4, CD8, CD25, and CD44 showed that both groups of chimeric mice presented normal DN and DP thymocyte development (Figure S10A). No significant difference in thymocyte cellularity was observed between Tcra−/−;Relb−/− and Tcra−/−;Relb+/− mice (data not shown). In these experiments, donor female Tcra−/− bone marrow cells were adaptively transferred to male recipients, so efficient thymus reconstitution by donor cells could be ascertained by the presence of X-chromosome-specific genomic sequences, as detected by PCR, and the absence of Y-chromosome-specific sequences in thymocytes from chimeric recipient mice (Figure S10B). These results indicate that Tcra and Relb double deficiency in non-hematopoietic cells does not impair the development of DN and DP thymocytes, the T-cell compartment targeted by TEL-JAK2 in leukemogenesis [25]. Thus, bone marrow cells from non-diseased EμSRα-TEL-JAK2;Tcra−/−;Relb−/− mice were intravenously injected into lethally irradiated Tcra−/−;Relb−/− and Tcra−/−;Relb+/− littermate recipient mice (Figure 6A). We found that Tcra−/−;Relb−/− recipient mice reconstituted with TEL-JAK2;Tcra−/−;Relb−/− bone marrow cells (TEL-JAK2;Tcra−/−;Relb−/−) developed T-cell leukemia with delayed onset, as compared to the reconstituted Tcra−/−;Relb+/− littersmates (TEL-JAK2;Tcra−/−;Relb+/−) (median survival of 46 and 23 weeks, respectively; P<0.01; Figure 6B). Two TEL-JAK2;Tcra−/−;Relb−/− mice even survived without leukemia for more than 60 weeks after transplantation (Figure 6B). PCR detection of the TEL-JAK2 transgene and the wild-type Relb allele in thymocytes from these mice showed effective donor bone marrow engraftment (data not shown). The two groups of mice developed severe dyspnea due to leukemic cell accumulation in the thymus and to pleural effusion containing leukemic cells (data not shown). Like the original TEL-JAK2 transgenic mice [21], diseased chimeric mice showed leukemic cell accumulation in the bone marrow, spleen, lungs, and liver (data not shown). Leukemic cells from both groups of mice expressed variable levels of CD4, CD8,
CD24, and CD25 cell surface markers, characteristic of bona fide TEL-JAK2 T-cell leukemia (data not shown). However, in addition to a delayed onset, TEL-JAK2;Tcra<sup>–/–</sup>;Relb<sup>–/–</sup> diseased mice presented significantly reduced accumulation of leukemic cells in the thymus and lymph nodes, as compared to TEL-JAK2; Tcra<sup>–/–</sup>;Relb<sup>+/+</sup> mice (Figure 6C), indicating that the disease evolved more slowly in lymphoid organs from RelB-deficient chimeras. A similar difference in tumor burden was observed in an independent experiment comparing leukemia development between Tcra<sup>–/–</sup>;Relb<sup>–/–</sup> and Tcra<sup>–/–</sup>;Relb<sup>+/+</sup> recipients (Figure S1). Taken together, these results show that RelB has a specific, non-redundant function in radiation-resistant thymic and lymph node stromal cells that facilitates TEL-JAK2-induced T-cell leukemogenesis.

**Discussion**

In the present study we have found that expression of the RelB transcription factor in non-hematopoietic, stromal cells promotes T-cell leukemogenesis induced by the TEL-JAK2 oncprotein. These conclusions stem from two sets of data showing delayed leukemia onset in (i) TEL-JAK2 transgenic mice deficient in RelB, as compared to RelB-proficient littermates, and (ii) lethally irradiated RelB-deficient mice reconstituted with TEL-JAK2 transgenic bone marrow, as compared to similarly reconstituted RelB-proficient littermates. These results thus demonstrate that, in addition to their reported pro-oncogenic role intrinsic to leukemic cells in several mouse models [16,34] and in human leukemia cell lines [12], NF-κB transcription factors contribute to T-cell leukemogenesis through the generation and/or maintenance of a proper stromal microenvironment.

Relb<sup>–/–</sup> mice develop lethal multiorgan inflammation shortly after birth [26,27]. This disease is caused by the appearance of autoreactive mature T cells resulting from the absence of mTECs expressing Aire transcriptional regulator-dependent peripheral tissue antigens, which are important to establish central self-tolerance [26–28,35]. The possibility that the delay in TEL-JAK2-induced leukemogenesis observed in RelB-deficient mice could be linked to the inflammatory phenotype of these mice can be excluded since our experiments were performed in the Tcra<sup>–/–</sup>-genetic background, which prevents the development of autoreactive T cells. Indeed, in contrast to the reported RelB-deficient phenotype [26–28], no significant inflammatory infiltrates were observed in the organs of Tcra<sup>–/–</sup>;Relb<sup>–/–</sup> mice.

Our previous results showed that TEL-JAK2 transforms immature DN and DP thymocytes [25]. Since DN and DP thymocyte development remained unaffected in the Tcra<sup>–/–</sup>; Relb<sup>–/–</sup> thymic microenvironment, we exclude the possibility that the delay in TEL-JAK2-induced leukemogenesis in RelB-deficient mice was simply due to a reduction in cellular targets available for oncogenic transformation. Our results thus suggest that the RelB-dependent microenvironment contributes specifically to DN/DP thymocyte transformation by TEL-JAK2.

Mouse RelB deficiency results in impaired lymphoid organ microarchitecture, affecting to varying degrees the development of thymus, spleen, lymph nodes, and Peyer’s patches [26,27,33]. Stromal defects in these lymphoid organs likely account for the observed delay in TEL-JAK2-induced leukemogenesis in Tcra<sup>–/–</sup>; Relb<sup>–/–</sup> mice. Since RelB-deficient diseased mice [both TEL-JAK2; Tcra<sup>–/–</sup>;Relb<sup>–/–</sup> mice and TEL-JAK2; Tcra<sup>–/–</sup>; Relb<sup>–/–</sup> chimeric mice] presented reduced thymic and lymph node tumor load compared to RelB-proficient controls, we conclude that defects in these organs were responsible for the delay in leukemogenesis.

Although lymph node development is strongly affected by the lack of RelB, the direct cellular defects associated with RelB deficiency in this organ are as yet unknown. In contrast, it has been shown that RelB-deficient thymi lack a defined medulla and mTECs and show a strong reduction in CD80/DEC205<sup>+</sup> dendritic cell (DC) numbers secondary to the defect in thymic architecture and mTECs [26,27,36]. Accordingly, Tcra<sup>–/–</sup>; Relb<sup>–/–</sup> mice showed no discernible thymic medulla and no UEA-1<sup>+</sup> mTECs. TCR<sub>±</sub>-deficient mice also show thymic architectural defects, with reduced and disorganized medulla and fewer UEA-1<sup>+</sup> mTECs than wild-type mice [11,31,32]. These defects are restored by adoptive transfer of mature T cells [11]. The combined deficiency of Tcra and Relb, but not Tcra deficiency alone [25], delayed TEL-JAK2-induced leukemia onset, thus indicating that, contrary to the RelB-deficient thymic defects, those found in TCR<sub>±</sub>-deficient mice have no detectable impact on leukemia development. Gray et al [31] have recently shown that TCR<sub>±</sub>-deficient thymi lack MHC II<sup>+</sup>/Ly51<sup>–</sup> (mTECs) cells, while
RelB-deficient thymi additionally lack MHC II/\textsuperscript{d}I\(\alpha\)51\(\textsuperscript{+}\) (mTEC\(\textsuperscript{b}\)) cells. It is thus tempting to speculate that specifically mTEC\(\textsuperscript{b}\) cells assist TEL-JAK2-induced T-cell leukemogenesis, although we cannot exclude an additional requirement for a RelB-dependent function in other stromal cells including DCs or cortical thymic epithelial cells. Moreover, RelB-deficient thymic stromal cells may assist TEL-JAK2 leukemogenesis either directly, through cell-cell contact or paracrine growth factor stimulation, or indirectly by stimulating other stromal cells (e.g., DCs) to interact with leukemic cells.

The nature of the molecular signals emanating from the thymic or lymph node stroma that favor T-cell leukemia initiation or progression remains to be identified. It is likely that RelB activity in mTEC or lymphoid organ stromal cells induces the expression of genes that favor T-cell leukemogenesis. Proteins known to play a role in thymic function include cytokine/growth factors (e.g., IL-7, Kit ligand, Notch ligands, and Sonic Hedgehog), chemokines (e.g., Ccl19/Elec, Ccl21/Slec, Ccl25/Teck, and Cxcl12/Sdf-1), cell surface receptors (e.g., LT\(\beta\)R, RANK, and Notch-1 to -3) and adhesion molecules (e.g., ICAM-1, MADCAM-1, and VCAM-1) [37,38]. RelB DNA-binding activity can be stimulated by RANK and LT\(\beta\)R, two receptors coupled to NF-kB activation and shown to be important for thymic medulla and lymphoid organ formation [39]. Both receptors activate NF-kB through the canonical and noncanonical pathways, with RANK specifically requiring TRAF6. LT\(\beta\)R signaling in thymic mTECs and in lymph node DCs induces expression of Ccl19 and Ccl21 [40,41], which are known RelB target genes [42,43], and of these chemokines as well as MAdCAM1, ICAM-1, and VCAM-1 in lymph node stromal cell organizers [44]. Since TEL-JAK2 leukemic cells express the Ccr7 transcript, encoding the receptor for the Ccl19 and Ccl21 chemokines (data not shown), and display cell surface expression of the ICAM-1 receptor LFA-1 (data not shown), it is tempting to speculate that these NF-kB signaling-dependent targets may play a role in TEL-JAK2-induced leukemogenesis.

Recent studies have shown that the composition of the thymic stroma is dynamic and modulated by particular stimuli (e.g., L1\(\text{\textalpha}\)\(\text{\textbeta}\), FGF family members, Wnt, and steroids) [45]. It is thus possible that leukemic T cells analogously induce qualitative and/or quantitative changes in thymic stromal populations. Our transcriptomic analysis showed higher expression levels of the L1\(\text{\textalpha}\) and L1\(\text{\textbeta}\)-encoding genes in TEL-JAK2 leukemic cells as compared to normal thymocytes [25] and data not shown. It is therefore possible that L1\(\text{\textalpha}\)\(\text{\textbeta}\) production by leukemic cells may modulate the thymic microenvironment in its favor through interaction with LT\(\beta\)R-expressing stromal cells and in this way contribute to leukemogenesis.

Our data cannot discriminate whether RelB-dependent stromal cells facilitate the initiation or the progression of T-cell leukemia, or both. Nevertheless, the limited tumor burden in thymus and lymph nodes of terminally ill TEL-JAK2;\(\text{Tcr}\alpha\text{\textalpha}\text{\textalpha}^{-/-};\text{Relb}\text{\textalpha}\text{\textalpha}^{-/-}\) and TEL-JAK2;\(\text{Tcr}\alpha\text{\textalpha}\text{\textalpha}^{-/-}\rightarrow\text{Tcr}\alpha\text{\textalpha}\text{\textalpha}^{-/-};\text{Relb}\text{\textalpha}\text{\textalpha}^{-/-}\) mice suggests that the RelB-dependent thymic microenvironment favors the expansion of transformed leukemic cells. During normal T-cell development, \(\text{Tcr}\alpha\text{\textalpha}\text{\textalpha}^{-/-}\text{Relb}\text{\textalpha}\text{\textalpha}^{-/-}\) thymi presented a slight reduction in thymocyte cellularity as compared to \(\text{Tcr}\alpha\text{\textalpha}\text{\textalpha}^{-/-}\text{Relb}\text{\textalpha}\text{\textalpha}^{-/-}\) thymi, suggesting that both normal and leukemic T-cell expansion is affected by RelB-dependent thymic stroma. The thymic medulla is a compartment where IL-7-dependent proliferation of mature T cells occurs before their export to the periphery [46,47]. This compartment in RelB-proficient TEL-JAK2 mice could favor the expansion of leukemic cells in the thymus.

Stromal cells from lymphoid organs or from the bone marrow are important to sustain survival and proliferation of human leukemic cells. The survival of T-ALL primary cells in vitro is promoted by exogenous growth factors (e.g., IL-7) or by co-culture with bone marrow or thymic stromal cells [48–51]. Also, thymectomy was shown to prevent T-cell leukemia development induced by Ikaros deficiency in mice [52], further supporting an important role of the thymic microenvironment in T-cell leukemia development. That tumor microenvironment-derived signals are required for the in vivo expansion of TEL-JAK2-induced leukemic cells is supported by the fact that these cells survived for over a week ex vivo but failed to proliferate under these conditions (data not shown).

TEL-JAK2 leukemic cells displayed NF-kB activity (p50, p52, RelA, and RelB), suggesting that, in addition to a noncell-autonomous role, NF-kB activation may also contribute cell-autonomously to TEL-JAK2 leukemia development or maintenance. Intrinsically canonical NF-kB activity has recently been shown to be important for Notch-induced murine T-cell leukemia, since disease development was inhibited by expression of the IxkB\(\alpha\) super-repressor mutant [16,34]. This effect could be specific to these particular models of T-cell leukemia, since the IxkB\(\beta\) super-repressor failed to affect Tal-1-induced T-ALL [15]. Transgenic co-expression of the IxkB\(\alpha\) super-repressor with TEL-JAK2 neither inhibited NF-kB activity nor affected leukemia incidence or severity (N.d.S., Marie Korner, and J.G., unpublished data). Likewise, \(\text{Nkb1}\) deficiency failed to affect TEL-JAK2-induced leukemogenesis. Interestingly, TEL-JAK2;\(\text{Nkb1}\text{\textalpha}^{-/-}\) leukemic cells did not present any RelA DNA-binding activity. In addition, RelA DNA-binding activity was reduced in TEL-JAK2;\(\text{Tcr}\alpha\text{\textalpha}\text{\textalpha}^{-/-}\) compared to TEL-JAK2;\(\text{Tcr}\alpha\text{\textalpha}\text{\textalpha}^{-/-}\) leukemic cells. These observations together with the fact that TCR\(\alpha\)-deficiency did not affect TEL-JAK2 leukemia onset [25], indicates that RelA DNA-binding activity correlates neither with leukemia time of onset nor with disease progression. In addition, bone marrow adoptive transfer experiments showed that RelB deficiency in hematopoietic cells did not affect TEL-JAK2-induced leukemogenesis. These results indicate that cell-autonomous RelB expression is not essential for TEL-JAK2 leukemia initiation or maintenance. However, since NF-kB functional redundancy may exist among the different members of the NF-kB family and since complete NF-kB activation could not be experimentally achieved in TEL-JAK2 leukemic cells, we cannot rule out that NF-kB plays a cell-autonomous role, in addition to a non-cell-autonomous role, in TEL-JAK2-induced leukemogenesis.

The p52 and RelB proteins are activated by the noncanonical NF-kB activation pathway, which depends on NIK/IKK\(\varepsilon\)-induced p100 processing. Accumulating evidence shows that the noncanonical NF-kB pathway is activated in the tumor cells of several human cancers, including B- and T-cell leukemia/lymphoma, mammary carcinoma, and prostate cancer [12,17,19,20,43,53,54]. The present results are however the first to uncover a role for RelB in the crosstalk between stromal and leukemic cells. Thus, the noncanonical NF-kB pathway may play a pro-oncogenic role both in tumor cells and in cells that compose the tumor microenvironment. In other settings, this property is shared by the canonical NF-kB activity which also plays an important role in activating both intrinsic genetic programs in cancer cells and the production of pro-oncogenic growth factors in cancer-associated stromal or inflammatory cells [3]. It will thus be important to understand how the thymic or lymphoid organ microenvironment assists T-cell leukemia development and to identify the leukemia-promoting factors that are dependent on noncanonical NF-kB activity in stromal cells. A better understanding of the crosstalk between leukemic T cells and stromal cells may pave the way for the development of new therapeutic strategies targeting this disease.
Materials and Methods

Mice

The EμSRα-TEL-JAK2 transgenic mice (line 71) [21] were bred with Tcrα (obtained from CNRS-CDTA; Orleàns, France), Robb [27], and Vβ11 [24] knock-out mice on the C57BL/6 background. All mice were maintained under specific-pathogen-free conditions in the animal facility of the Institut Curie (Orsay, France). All experimental procedures were performed in strict accordance with the recommendations of the European Community (86/609/EEC) and the French National Committee (87/848) for the care and use of laboratory animals. All animal experiments were carried out under the supervision of J.G., who was authorized by the director of the Veterinary Services of the Préfecture de l’Essonne (agreement number 91-7). TEL-JAK2 transgenic mice were euthanized when terminally ill, due to either severe dyspnea caused by massive expansion of leukemic cells in the thymus or extreme weakness caused by leukemic dissemination to vital organs such as bone marrow, lung, and liver. Statistical analyses and survival curves were calculated using Prism 4 (GraphPad, San Diego, CA). Genomic PCR of the sex chromosome-localized Jarid1c/Kdm5c and Jarid1d/Kdm5d genes was performed as described by Clapcote and Roder [55].

Bone marrow adoptive transfer experiments

Mouse bone marrow cells (BMC) were flushed out from hind legs. TEL-JAK transgenic BMC were obtained from nondiseased 4-week-old mice, as verified by the absence of leukemic cells (CD4+CD8+CD255) in the thymus and bone marrow by flow cytometry. In adoptive transfer experiments, 2–3×10^8 BMC were intravenously injected into lethally irradiated (8.125 Gy) mice using an IBL-637 (137Cs) irradiator (CIS-BioInternational, Santa Cruz, CA) were incubated with binding reactions for 10 min on ice before electrophoresis.

Flow cytometry

Single cell suspensions from lymphoid organs were stained with fluorochrome-labeled antibodies and detected by a FACScalibur cytometer (BD Biosciences, San Jose, CA) as previously described [21]. Fluorescein isothiocyanate (FITC)-, R-phycocerythrin (PE)-, PE-cyanine 5 (PE-Cy5)- or allophycocyanin (APC)-conjugated antibodies specific for CD90.2/Thyl.1 (32-2.1) CD4 (H129.19), CD8α (53-6.7), CD3e (145-2C11), TCRβ (H57-597), TCRγδ (GL3), CD5 (53-7.3), CD24/HSAA (M1/69), and CD25/IL-2Rα (7D4) (BD Biosciences) were used. The data were analyzed using CellQuest (BD Biosciences) and FlowJo (Tree Star, Ashland, OR).

Histopathological and immunohistochemical analyses

Histopathological analyses were performed essentially as previously described [21]. For immunohistochemistry, 6-μm formalin-fixed, paraffin-embedded, thymus sections were deparaffinized and hydrated. After each of the following incubations the slides were rinsed with several changes of PBS. Sections were blocked with 0.3% H2O2 in PBS for 15 min, followed by 0.5% casein in PBS for 15 min and incubated with 1:50 biotinylated UEA-1 lectin for 2 h at room temperature followed by ABC peroxidase for 30 min. Sections were visualized by DAB staining, counterstained with Meyers hematoxylin, dehydrated and mounted in non-aqueous mounting media. All staining reagents were obtained from Vector Labs (Burlingame, CA).

Supporting Information

Figure S1  TEL-JAK2 leukemic cells do not show c-Rel DNA-binding activity. (A) NF-κB activity (bands I and II, indicated by arrowheads) in nuclear extracts obtained from leukemic cells from a representative TEL-JAK2 tumor (n=20) does not include c-Rel, as shown by supershift analysis using the indicated antibodies. (B) The same c-Rel antibody supershifted an NF-κB complex (open arrowheads) in thymocytes stimulated for 24 h by 5 μg/ml PMA plus 250 ng/ml ionomycin. Found at: doi:10.1371/journal.pone.0002555.s001 (2.30 MB TIF)

Figure S2  TEL-JAK2, Vβ11-/- leukemic cells activate RelA when stimulated with PMA plus ionomycin. (A) TEL-JAK2, Vβ11-/- leukemic cells were stimulated for the indicated period of time with 50 ng/ml PMA plus 500 ng/ml ionomycin and nuclear extracts were analyzed by EMSA using the Igκ-B and Sp1 probes. (B) PMA plus ionomycin stimulation for 30 min induced RelA and p52. RelA-containing complexes are indicated by arrows. The p32:RelB complexes (band II) were shown by arrowheads. Found at: doi:10.1371/journal.pone.0002555.s002 (2.26 MB TIF)
Figure S3 Histological analysis of Tcra−/−;Relb−/− and control mice. (A) H&E staining of liver (a–c) and lung (d–f) from mice of the indicated genotypes reveals an absence of inflammatory infiltrates in Tcra−/−;Relb−/− mice. (B) H&E staining of mesenteric lymph nodes (a–c) from mice of the indicated genotypes shows rudimentary lymph nodes in Relb-deficient mice, as compared to Relb-proficient mice. Also note the presence of B-cell follicles in RelB-proficient lymph nodes (arrowheads).

Figure S4 TCRγ6 T cells develop normally in Tcra;Relb double deficient thymus. TCRγ6 and CD5 cell surface immunostaining of gated Thy1.2+CD4/CD8 double negative cells of representative mice of the indicated genotypes. Found at: doi:10.1371/journal.pone.0002555.s003 (9.62 MB TIF)

Figure S5 NF-κB activity in TEL-JAK2 leukemic cells depends on γδTCR expression. (A) Leukemic cell nuclear extracts from representative TEL-JAK2;Tcra−/− and TEL-JAK2;Tcra+ mice were analyzed by EMSA using the Ig-κB probe (left) and Sp1 probes. (B) Antibody supershift analysis of Ig-κB-bound complexes using the indicated antibodies was performed on nuclear extracts from representative TEL-JAK2;Tcra−/− leukemic cells. l and H indicate migrating DNA-bound NF-κB complexes. Found at: doi:10.1371/journal.pone.0002555.s004 (2.52 MB TIF)

Figure S6 Diseased Relb-deficient and Relb-proficient TEL-JAK2 mice show similar macroscopic appearance. The thymus (a,b), spleen (c,d), and lung (e,f) of a representative mouse of each indicated genotype is shown. Note the massive invasion of the organs by leukemic cells. Arrowheads indicate areas of leukemic cell infiltration in the lungs.

Figure S7 Relb-deficient and Relb-proficient TEL-JAK2 leukemic cells present a similar cell surface marker phenotype. (a–f) Cell surface staining with CD4 and CD8 antibodies of wild-type thymocytes (a), two representative TEL-JAK2;Tcra−/−;Relb−/− mice (b,c), and three representative TEL-JAK2;Tcra−/−;Relb−/− mice (d–f). (g–j) Cell surface staining with CD24 or CD25 antibodies of two representative TEL-JAK2;Tcra−/−;Relb−/− mice (top panels), and three representative TEL-JAK2;Tcra−/−;Relb−/− mice (bottom panels).

Figure S8 Relb deficiency in the hematopoietic compartment does not affect leukemic cell accumulation in lymphoid organs. Diseased mice adoptively transferred with Relb-deficient TEL-JAK2;Tcra−/− bone marrow cells (TELJAK2;Tcra−/−;Relb−/−→WT) presented lymphoid organ tumors of similar weight as mice transfected with TEL-JAK2;Tcra−/−;Relb−/− bone marrow (TELJAK2;Tcra−/−;Relb−/−→WT). Thymus and lymph node weights were plotted for each group of mice. The number of analyzed mice is given between parentheses.

Figure S9 Efficient thymocyte development in wild-type mice adoptively transferred with either Tcra−/−;Relb−/− or Tcra−/−;Relb−/− bone marrow cells. Top panels: CD4 and CD8 immunostaining shows a very low proportion of SP (host) thymocytes in representative pairs of recipient wild-type (WT) mice, indicating that the majority of thymocytes originated from donor hematopoietic cells given that TCRα2 deficiency blocks DP to SP transition. Bottom panels: CD25 and CD44 staining of gated CD4/CD8 DN cells of representative WT mice reconstituted with either Tcra−/−;Relb−/− or Tcra−/−;Relb−/− bone marrow. Note that the RelB mutation does not significantly affect early thymocyte development.

Figure S10 Normal double negative and double positive thymocyte development in bone marrow-reconstituted Tcra−/−; Relb−/− and Tcra−/−;Relb−/− mice. (A) CD4, CD8 cell surface immunostaining of total thymocytes (top panels) and CD24, CD44 staining of Thy1.2+, CD4/CD8 DN cells (bottom panels) of representative pairs of Tcra−/−→Tcra−/−;Relb−/− and Tcra−/−→Tcra−/−;Relb−/− chimeric mice. (B) Thymocytes from chimeric recipient male mice of the indicated genotypes that received bone marrow cells from female Tcra−/− mice were analyzed by PCR amplification of the Jarid1c/Kdm5c and Jarid1d/Kdm5d genes. The upper band derived from the Jarid1c gene, located on the X chromosome, while the lower band derived from the Jarid1d gene, located on the Y chromosome [55]. Note the full reconstitution of recipient male thymus with thymocytes of donor (female) origin.

Figure S11 TEL-JAK2-induced T-cell lymphoid tumors are smaller in Tcra−/−;Relb−/− than Tcra−/−;Relb−/− recipient mice. (A) Kaplan-Meier leukemia-free survival curves for Tcra−/−; Relb−/− and Tcra−/−;Relb−/− chimeric mice that received bone marrow from EquSRα2;TEL-JAK2;Tcra−/− transgenic mice (median survival of 211 and 164 days, respectively; log-rank test, P value = 0.1016). The number of mice in each group is given between parentheses. (B) Thymus and lymph node weights were plotted for TEL-JAK2;Tcra−/−→Tcra−/−;Relb−/− and TEL-JAK2;Tcra−/−→Tcra−/−;Relb−/− chimeric mice that developed T-cell leukemia/lymphoma. **, P value<0.01; ***, P value<0.001 (unpaired t-test). The number of mice analyzed is given between parentheses.

Acknowledgments
We thank Christophe Alberti, Yveline Bourgeois, Noaura Mebirouk, and Josiane Ropers for assistance with mouse husbandry and handling and Mai Thao Bui and Elena Zinovieva for technical help. We also thank John Hiscott, Marie Körner, and Nancy Rice for providing reagents, Philippe Naquet for helpful discussions, and Véronique Bal and Philippe Kastner for critically reading the manuscript. We thank other Glysdael laboratory members for helpful discussions and continuous support.

Author Contributions
Conceived and designed the experiments: JG Nd. Performed the experiments: Nd MW FC DW SG. Analyzed the data: AJ JG Nd FW. Contributed reagents/materials/analysis tools: JG Nd FW. Wrote the paper: JG Nd.
lymphoconut-beta receptor activation: critical roles for p100. J Biol Chem 278: 23276–23284.
7. Muller JR, Siebenlist U (2003) Lymphoconut beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. J Biol Chem 278: 13006–13012.
8. Dejardin E (2000) The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 72: 1161–1179.
9. Anderson G, Lane PJ, Jenkinson EJ (2007) Generating intrathymic microenvironments to establish T-cell tolerance. Nat Rev Immunol 7: 954–963.
10. Naquet P, Naspetti M, Boyd R (1999) Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
11. Naquet P, Naspetti M, Boyd R (2000) Development and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
12. Lacronique V, Boureux A, Della Valle V, Poirel H, Quang CT, et al. (1997) A new Rel family transcription activator that can interact with p50-NF-kappa B. EMBO J 16: 3650–3659.
13. Ryseck R-P, Bull P, Takamiya M, Bours V, Siebenlist U, et al. (1992) RelB, a member of the NF-kappa B/Rel family. Cell 80: 735–743.
14. Sha WC, Liou H-C, Tuomanen EI, Baltimore D (1995) Targeted disruption of relB is required for the development of thymic medulla and dendritic cells. Immunity 2700–2707.
15. Xiao G, Rabson AB, Young W, Qing G, Qiu Z (2006) Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev 17: 281–293.
16. Sha WC, Liou H-C, Tuomanen EI, Baltimore D (1995) Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Cancer Cell 12: 115–130.
17. Sha WC, Liou H-C, Tuomanen EI, Baltimore D (1995) Targeting the NF-kappaB signaling pathway in multiple myeloma. Cancer Cell 12: 115–130.
18. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131–144.
19. Carrasco D, Rizzo CA, Dorfman K, Bravo R (1996) The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J 15: 3640–3650.
20. Carreño C, Corominas F, Janin A, Lacrouix V, Giovannini M, et al. (2000) TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95: 3089–3099.
21. Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang X, Shin SR, et al. (2004) Ikaros-deficient mice. Mol Cell Biol 26: 209–220.
22. Sha WC, Liou H-C, Tuomanen EI, Baltimore D (1995) Targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80: 735–743.
23. Bellavita D, Cambesi F, Alessi E, Varca A, Felli MP, et al. (2000) Constitutive activation of NF-kappaB in T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 19: 3337–3348.
24. Anderson G, Lane PJ, Jenkinson EJ (2007) Generating intrathymic microenvironments to establish T-cell tolerance. Nat Rev Immunol 7: 954–963.
25. Weih F, Caamano J (2005) Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol Rev 195: 91–105.
26. Heino M, Peterson P, Sillanpaa N, Guerin S, Wu L, et al. (2000) RNA and protein expression of the murine autoimmune regulator gene (Arex) in normal, autoimmune, and in NOG mouse. Eur J Immunol 30: 1184–1193.
27. Matsumoto K, Kikutani H, Yamasaki H, Itoh H, Tanaka S, et al. (1993) Cloning and expression of a murine autoimmune regulator gene. Eur J Immunol 23: 23278–23284.
28. Naquet P, Naspetti M, Boyd R (1999) Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
29. Naquet P, Naspetti M, Boyd R (2000) Development and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
30. Naquet P, Naspetti M, Boyd R (1999) Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
31. Naquet P, Naspetti M, Boyd R (2000) Development and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
32. Naquet P, Naspetti M, Boyd R (1999) Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
33. Naquet P, Naspetti M, Boyd R (2000) Development and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
34. Naquet P, Naspetti M, Boyd R (1999) Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
35. Naquet P, Naspetti M, Boyd R (2000) Development and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
36. Naquet P, Naspetti M, Boyd R (1999) Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
37. Naquet P, Naspetti M, Boyd R (2000) Development and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.